Quarterly report pursuant to Section 13 or 15(d)

Organization and Summary of Significant Accounting Policies (Details Narrative)

Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)
$ in Thousands
1 Months Ended 9 Months Ended
Aug. 15, 2022
Sep. 30, 2023
Sep. 30, 2023
Dec. 31, 2022
Sep. 30, 2022
Jul. 31, 2022
Severance payments     $ 247      
Cash and cash equivalents   $ 8,096 8,096 $ 2,937 $ 4,450  
Raw materials and supplies and finished goods inventory   106    
Money Market Funds [Member] | Fair Value, Recurring [Member]            
Fair value of investments       $ 2,600    
Rubin [Member]            
Severance payments $ 400          
Pro Neura [Member]            
Asset sale description   we entered into an asset purchase agreement (the “Asset Purchase Agreement”) with Fedson, Inc., a Delaware corporation (“Fedson”) for the sale of the ProNeura Assets. Our addiction portfolio consisted of the Probuphine and Nalmefene implant programs. The ProNeura Assets constituted only a portion of our assets. In August 2023, we entered into an Amendment and Extension Agreement (the “Amendment”) to the Asset Purchase Agreement, pursuant to which Fedson agreed to purchase our ProNeura Assets for a purchase price of $2.0 million, consisting of (i) $500,000 in readily available funds, paid in full on the Closing Date, (ii) $500,000 in the form of a promissory note due and payable on October 1, 2023 (the “Cash Note”) and (iii) $1,000,000 in the form of a promissory note due and payable on January 1, 2024 (the “Escrow Note”). We will also be eligible to receive potential milestone payments of up to $50 million on future net sales of the products and certain royalties on future net sales of the products. As further consideration, Fedson assumed all liabilities related to a pending employment claim against us. On the Closing Date, Fedson delivered a written guaranty by a principal of Fedson of all of Fedson’s obligations under both the Cash Note and Escrow Note. The Cash Note included provisions, which Fedson has exercised, allowing Fedson to extend the payment of the Cash Note to November 1, 2023 and again to December 1, 2023 upon payment of $5,000 for each extension. The Cash Note is currently due and payable on December 1, 2023. The Cash Note and Escrow Note are included in Notes Receivable in the condensed balance sheet at September 30, 2023.        
David Lazar and Activist Investing LLC [Member]            
Ownership interest by Activist           25.00%